causal

Big pharma as forced buyer of startups

Over the past 20 years big pharma divested most internal early-stage R&D and pivoted to buying startups from private markets or public biotechs, creating a forced buyer spending $20 to $30 billion a year and a structural opportunity for venture capital because patent cliffs require replacing expiring products.

causalpending

Speaker

D.A.

Evidence Quote

“all of the big pharma companies almost to a one have divested from internal research and development, especially at the early stages”

Source

Investing in Healthcare— Invest Like the Best
Created: 11/17/2026, 5:03:43 PM

Your notes

Loading notes...